X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dishman Pharma with Aventis Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs SANOFI INDIA - Comparison Results

DISHMAN PHARMA    Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA SANOFI INDIA DISHMAN PHARMA/
SANOFI INDIA
 
P/E (TTM) x 25.1 39.9 62.9% View Chart
P/BV x 3.3 8.6 38.9% View Chart
Dividend Yield % 0.7 1.0 63.4%  

Financials

 DISHMAN PHARMA   SANOFI INDIA
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
SANOFI INDIA
Dec-16
DISHMAN PHARMA/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs3744,560 8.2%   
Low Rs1294,400 2.9%   
Sales per share (Unadj.) Rs197.81,028.5 19.2%  
Earnings per share (Unadj.) Rs21.2129.0 16.4%  
Cash flow per share (Unadj.) Rs34.7186.0 18.7%  
Dividends per share (Unadj.) Rs2.0068.00 2.9%  
Dividend yield (eoy) %0.81.5 52.4%  
Book value per share (Unadj.) Rs179.9753.6 23.9%  
Shares outstanding (eoy) m80.6923.03 350.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.34.4 29.2%   
Avg P/E ratio x11.934.7 34.2%  
P/CF ratio (eoy) x7.224.1 30.1%  
Price / Book Value ratio x1.45.9 23.5%  
Dividend payout %9.452.7 17.9%   
Avg Mkt Cap Rs m20,306103,174 19.7%   
No. of employees `0000.83.6 22.9%   
Total wages/salary Rs m5,3553,592 149.1%   
Avg. sales/employee Rs Th19,252.76,537.7 294.5%   
Avg. wages/employee Rs Th6,459.5991.4 651.5%   
Avg. net profit/employee Rs Th2,064.1819.8 251.8%   
INCOME DATA
Net Sales Rs m15,96123,686 67.4%  
Other income Rs m265708 37.5%   
Total revenues Rs m16,22624,394 66.5%   
Gross profit Rs m4,1035,281 77.7%  
Depreciation Rs m1,0911,313 83.1%   
Interest Rs m94415 6,296.0%   
Profit before tax Rs m2,3344,661 50.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6241,691 36.9%   
Profit after tax Rs m1,7112,970 57.6%  
Gross profit margin %25.722.3 115.3%  
Effective tax rate %26.736.3 73.7%   
Net profit margin %10.712.5 85.5%  
BALANCE SHEET DATA
Current assets Rs m11,01815,673 70.3%   
Current liabilities Rs m9,5176,678 142.5%   
Net working cap to sales %9.438.0 24.8%  
Current ratio x1.22.3 49.3%  
Inventory Days Days11076 145.4%  
Debtors Days Days3522 156.1%  
Net fixed assets Rs m16,3048,098 201.3%   
Share capital Rs m161230 70.1%   
"Free" reserves Rs m12,90717,088 75.5%   
Net worth Rs m14,51617,356 83.6%   
Long term debt Rs m4,1890-   
Total assets Rs m29,80525,400 117.3%  
Interest coverage x3.5311.7 1.1%   
Debt to equity ratio x0.30-  
Sales to assets ratio x0.50.9 57.4%   
Return on assets %8.911.8 75.8%  
Return on equity %11.817.1 68.9%  
Return on capital %17.526.9 65.1%  
Exports to sales %24.824.5 101.2%   
Imports to sales %3.728.0 13.4%   
Exports (fob) Rs m3,9565,801 68.2%   
Imports (cif) Rs m5966,627 9.0%   
Fx inflow Rs m4,9527,145 69.3%   
Fx outflow Rs m6976,846 10.2%   
Net fx Rs m4,255299 1,423.0%   
CASH FLOW
From Operations Rs m2,7863,226 86.4%  
From Investments Rs m-1,529-1,555 98.3%  
From Financial Activity Rs m-941-1,818 51.8%  
Net Cashflow Rs m316-147 -215.2%  

Share Holding

Indian Promoters % 61.4 0.0 -  
Foreign collaborators % 0.0 60.4 -  
Indian inst/Mut Fund % 3.7 14.4 25.7%  
FIIs % 12.7 14.6 87.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 10.5 210.5%  
Shareholders   46,261 15,184 304.7%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   SUVEN LIFE  SHASUN PHARMA  PFIZER  TTK HEALTHCARE  SUN PHARMA  

Compare DISHMAN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

SANOFI INDIA Announces Quarterly Results (1QFY19); Net Profit Up 35.1% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, SANOFI INDIA has posted a net profit of Rs 996 m (up 35.1% YoY). Sales on the other hand came in at Rs 7 bn (up 13.8% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA Announces Quarterly Results (4QFY18); Net Profit Up 37.5% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, SANOFI INDIA has posted a net profit of Rs 825 m (up 37.5% YoY). Sales on the other hand came in at Rs 6 bn (up 11.7% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 5-YR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS